South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Investment is additive to KKR’s existing health care growth strategy
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Increased capability to produce medicines for challenging diseases including cancer
Subscribe To Our Newsletter & Stay Updated
